Latest News

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Modulim Announces CE Mark of Clarifi Imaging System for Microvascular Assessment

Modulim can now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Genius AI Detection Receives FDA Clearance

Hologic notes the new technology which the company has now made commercially available represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam.

FDB Releases Patient-Specific Medication Decision Support Solution for Use in EHR Workflow

FDB (First Databank, Inc.) announced the release of targeted medication decision support that provides clinicians with more meaningful guidance at the most appropriate time in the clinical workflow. FDB’s Targeted Medication Warnings leverage patient-specific, contextual clinical information within the EHR to identify only the patients that manifest the prescribing risk, so that resulting clinical guidance is more meaningful and actionable. At present, five hospital systems have integrated FDB’s Targeted Medication Warnings. The company is a provider of drug and medical device knowledge that helps healthcare professionals make precise decisions.

Medication decision support within healthcare IT systems has been limited due to the lack of availability of broader patient information, so knowledge bases and IT systems only considered the drug with limited clinical context. Integrating patient record information presents broader possibilities to be more specific and targeted and to take a “patient first” approach. The benefits are significant because as clinical decision support (CDS) incorporates more patient context, such as lab values or clinical risk scores, it becomes more meaningful and therefore more likely to be acted upon. This new, more targeted approach is designed to improve the positive predictive value of alerts and improve clinician efficiency over current CDS methods.

“We are thrilled with the reception that our newest approach to medication decision support guidance has already received,” said Chuck Tuchinda, MD, MBA, executive vice president, Hearst Health and president, FDB. “Our goal in creating medication guidance that is actionable, targeted and patient-specific, is to ensure it becomes more meaningful and less likely to be overridden by clinicians, which ultimately will lead to enhanced patient care and improved clinical outcomes.”

The new targeted medication decision support from FDB focuses on high-risk clinical scenarios such as hyperkalemia, QT prolongation, opioid use, pharmacogenomics, and more. Patient-specific information, such as lab values and clinical risk assessments, are pulled into the guidance to provide actionable information at the right time in the workflow. Traditional medication alerts that do not apply will be demoted when Targeted Medication Warnings are implemented in the EHR, so that end users are trading broader alerts for those that are more targeted.

Currently available for Epic health system customers, FDB Targeted Medication Warnings can also integrate with other technology solution providers. To learn more about our patient-first approach to medication decision support, please visit us at HIMSS19, and join us for a wine reception, Wednesday, February 13, 2019, 4:30 – 6:00pm in booth #1921.

Latest Posts

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...